S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Is Gold Really Boring? (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Is Gold Really Boring? (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Is Gold Really Boring? (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Is Gold Really Boring? (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Elon Musk Gives Profanity-Laden Tirade During DealBook Interview: "Go F--- Yourself'

BerGenBio ASA Stock Price, News & Analysis (OTCMKTS:BRRGF)

$0.03
0.00 (0.00%)
(As of 11/30/2023 ET)
Compare
Today's Range
$0.03
$0.03
50-Day Range
$0.03
$1.77
52-Week Range
$1.77
$2.35
Volume
N/A
Average Volume
200 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BRRGF stock logo

About BerGenBio ASA Stock (OTCMKTS:BRRGF)

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

BRRGF Stock Price History

BRRGF Stock News Headlines

BerGenBio ASA BGBIO
BerGenBio Reports Third Quarter 2023 Financial Results
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
H.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
BerGenBio AS (BRRGF) Gets a Buy from H.C. Wainwright
See More Headlines
Receive BRRGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRRGF
CIK
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Martin Olin (Age 54)
    Chief Executive Officer
    Comp: $885.96k
  • Mr. Rune Skeie (Age 50)
    Chief Financial Officer
    Comp: $241.04k
  • Dr. James Barnes Ph.D.
    Chief Operating Officer
  • Ms. Gayle M. Mills M.B.A (Age 68)
    Chief Business Officer
  • Ms. Cristina Oliva M.D.
    Chief Medical Officer
  • Graham Morell
    Head of IR
  • Dr. Akil Jackson
    Medical Director














BRRGF Stock Analysis - Frequently Asked Questions

Should I buy or sell BerGenBio ASA stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" BRRGF shares.
View BRRGF analyst ratings
or view top-rated stocks.

How have BRRGF shares performed in 2023?

BerGenBio ASA's stock was trading at $1.77 on January 1st, 2023. Since then, BRRGF shares have decreased by 98.6% and is now trading at $0.0250.
View the best growth stocks for 2023 here
.

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BRRGF) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -